28 results
Thumbnail

D3.230 - Type I Hypersensitivity Among Private Dental Practitioners: Clinical Manifestations and Associated Factors

Thumbnail

D3.221 - Cat Immunotherapy and Real-Life Data: A Single-Center Experience

Thumbnail

D3.220 - Real-World Management of Pediatric Allergic Diseases: A Nationwide Physician Survey among Allergists and Pediatric Allergists in Turkey

Thumbnail

D3.215 - Shifting patterns of mite sensitization in Southern Europe: Real-World diagnostic and immunotherapy practices in Spain and Portugal (MITE-WISE Project)

Thumbnail

D3.216 - Determination of Allergenic Activity of Native Mugwort Allergen Preparations by a Competitive IgE-Binding Test

Thumbnail

D3.217 - Development and validation of a monoclonal antibody-based competitive ELISA to accurate quantification of Blo t 2 in native Blomia tropicalis allergenic extracts

Thumbnail

D3.218 - When the sting is not the sensitizer: a vespid venom allergy case

Thumbnail

D3.222 - Monitoring the immune response during the first year of SCIT in Ragweed allergy

Thumbnail

D3.223 - Crossroads of Venom and Bite: A case of Horsefly - Wasp Cross - reactive Anaphylaxis

Thumbnail

D3.225 - Two years Sublingual SQ-Grass Pollen Tablet Immunotherapy Combined with Dupilumab Induces Longterm Suppression of Immediate Cutaneous Allergen Sensitivity

Thumbnail

D3.226 - Prophylactic sublingual peanut immunotherapy alters antibody responses and downstream allergen reactivity in a Brown Norway rat model

Thumbnail

D3.227 - The effect of subcutaneous allergen immunotherapy after one year on the quality of life of children with perennial allergic rhinitis and rhinoconjunctivitis

Thumbnail

D3.228 - One-Year Changes in Molecular sIgE Profiles During House Dust Mite Immunotherapy: A Pilot Study

Thumbnail

D3.229 - Comparison of mold sensitization profiles in children (2021 and 2025): impact of environmental deterioration during martial law

Thumbnail

D2.449 - Patients with Inadequately Controlled CRSwNP and Blood Eosinophil Count ≥150 cells/µL Experience Benefit with Depemokimab: An Analysis of Data from the Integrated ANCHOR-1/-2 Studies

Thumbnail

D2.447 - Phenotyping of Chronic T2 Inflammatory Diseases of the Nose and Paranasal Sinuses and the Algorithm for Biologic Therapy Selection

Thumbnail

D2.448 - Recommendations on Patient Education for Biological Therapy in CRSwNP – An EAACI Position Paper

Thumbnail

D2.450 - EUFOREA/EPOS Criteria Applied to a Diverse CRSwNP Cohort: Post Hoc Findings from Twice-Yearly depemokimab ANCHOR-1/-2 trials

Thumbnail

D2.451 - Real-life upper and lower airway outcomes of long-term dupilumab treatment in patients with severe chronic rhinosinusitis with nasal polyps

Thumbnail

D2.452 - Real-World Trends in the Epidemiology and Burden of Chronic Rhinosinusitis with Nasal Polyps Over Time in Germany Reveal Increasing Prevalence and Low Biologic Use